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Neonatal diabetes is a heterogeneous group of disorders with diabetes manifestation before 6 months of life that most frequently has a monogenic etiology ([@r1]). In patients with permanent neonatal diabetes (i.e., without remission) (PND), mutations of the K~ATP~ channel subunits (encoded by the *KCNJ11* and *ABCC8* genes) and mutations of the insulin gene are the most common etiology ([@r1]). Transient neonatal diabetes (TND) usually resolves by 6 months of age, but more than 50% of TND patients relapse into diabetes during childhood or adulthood ([@r2]). Abnormalities of the imprinted region, 6q24, which encompasses the *ZAC* and *HYMAI* genes, cause ∼70% of TND cases ([@r3]). Mutations of K~ATP~ channel subunits are the second most common etiology ([@r3]).

RESEARCH DESIGN AND METHODS
===========================

We report on a patient who was born with a birth weight of 2,320 g at 38 weeks\' postgestation (\<3rd centile). Because of the low birth weight, she required hospitalization at the newborn care unit. She was diagnosed with diabetes without ketoacidosis on the fourth day of postnatal life (blood glucose 19.5 mmol/l). The initial treatment was intravenous insulin (0.04 units · kg^−1^ · h^−1^), followed by subcutaneous injections of NPH insulin (0.9 units · kg^−1^ · day^−1^).

RESULTS
=======

At the age of 2 weeks and following a clinical diagnosis of neonatal diabetes, analysis of the *KCNJ11* gene was undertaken ([@r3]). We found a novel, heterozygous missense mutation, R365H (c.1094G\>A; p.Arg365His), in the proband. The mutation was present in the unaffected father and paternal grandfather ([Fig. 1](#f1){ref-type="fig"}). Standard oral glucose tolerance tests revealed a normal glucose tolerance with normal insulin and C-peptide values in the parents and paternal grandmother, but the paternal grandfather had impaired fasting glycemia combined with impaired glucose tolerance (0-h glycemia 5.8 mmol/l; 2-h glycemia 9.4 mmol/l).

K~ATP~ channel mutations causing TND in the proband and adult-onset diabetes in a parent and/or grandparent have been previously reported ([@r3]). The R365H mutation identified in our family was thought likely to be pathogenic because the arginine residue at codon 365 is conserved in dog, rat, and mouse, was not present in 298 control chromosomes, and has not previously been reported in patients with hyperinsulinism. Therefore, in vitro functional studies of this mutation were undertaken. Channels containing the R365H mutation were expressed in Xenopus oocytes and their surface density, activation by the metabolic inhibitor azide, and blocking by the sulfonylurea tolbutamide were measured ([@r4]). Unexpectedly, there was no difference between the wild-type and mutant channels, which calls into question the pathogenicity of this mutation.

In the meantime, the patient developed hypoglycemia on insulin treatment, and at the age of 7 months, the insulin therapy was discontinued. The nine-value 24-h glycemic profile 7 months after stopping insulin administration was normal (4.7--4.1--5.5--7.8--7.6--7.1--3.9--5.3--5.2 mmol/l), and A1C was 4.3% (within the Diabetes Control and Complications Trial range), (high-performance liquid chromatography, Variant II; Biorad, Hercules, CA, U.S.). Currently, with the subject at the age of 2 years, A1C is 5.1%. No glycosuria has been noted on repeated testing.

Thus, we had to revise our initial diagnosis of PND due to a *KCNJ11* mutation ([@r3]). Genetic analysis of the methylation status within the TND critical region on chromosome 6 was performed using the methylation-specific PCR method, as previously described ([@r5]). A 6q24 duplication was identified, and family member testing demonstrated that the duplication was also present in the unaffected father and paternal grandmother ([Fig. 1](#f1){ref-type="fig"}).

CONCLUSIONS
===========

We report a novel *KCNJ11* variant (R365H) and a 6q24 duplication in a proband with TND and her unaffected father. The paternally inherited 6q24 duplication is likely to be the etiological mutation as a consequence of overexpression of paternal genes within the duplicated chromosome 6q24 region. Expression of genes in this region is regulated by imprinting. The maternal allele is methylated and therefore inactive: only genes on the paternally derived chromosome are transcribed. Normal development depends on normal doses of gene transcripts. The proband′s father is unaffected because his 6q24 duplication is maternally inherited and, therefore, inactive ([@r2]). The impaired fasting glycemia and impaired glucose tolerance in the paternal grandfather may be influenced by his age (53 years), weight (BMI 28.5 kg/m^2^), and maternal history of type 2 diabetes. We conclude that the R365H is likely to be a rare variant of no clinical significance.

In PND patients, screening of the *KCNJ11* mutations is recommended, and if it is negative, mutations in other genes should be investigated (e.g., insulin gene, *ABCC8*, etc.) ([@r1],[@r6]). In the case of TND, K~ATP~ channel genes should be tested if 6q24 analysis is negative. Our case report highlights the difficulty in testing neonates before the clinical course (transient versus permanent) is known and when no supportive signs (e.g., macroglossia and umbilical hernia in 6q24 abnormalities \[[@r2]\]) are present. Thus, in these patients, we recommend screening for *KCNJ11* gene mutations and 6q24 abnormalities simultaneously, as making the genetic diagnosis earlier may influence treatment (patients with K~ATP~ channel mutations are often sensitive to sulfonylureas, while patients with 6q24 abnormalities are usually treated with insulin \[[@r2],[@r3]\]). Finally, when a novel mutation in a known gene is found, functional studies and investigations of other neonatal diabetes genes can play an important role.
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![Pedigree of the family with coincidence of the novel R365H variant of the *KCNJ11* gene and the 6q24 duplication. Nature of hyperglycemia: neonatal diabetes. The *KCNJ11* genotype is shown under each symbol. The 6q24 status is shown below. An arrow points to the proband. The proband, the proband\'s father, and the proband\'s paternal grandfather are carriers of the R365H mutation. The proband also has a paternally inherited 6q24 duplication. The proband\'s father has a maternally derived 6q24 duplication. The paternal grandfather has both impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), which seem to be associated with older age or type 2 diabetes diagnosis and not with the R365H mutation of the *KCNJ11* gene. •, TND; ▒, IFG + IGT. NN, no mutation identified.](zdc0090871570001){#f1}
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